Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson
Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares (CANF)
NASDAQ:AMEX Investor Relations:
ir.canfite.com
Company Research
Source: Business Wire
The study did not achieve its primary end point of median overall survival in the whole population of 78 patients, however, superiority in median overall survival was found in the largest study subpopulation of 56 patients and in secondary end points including objective response in the whole population, strongly supporting the progression into Phase III. Dr. Josep Llovet, a Key Opinion Leader in the field of liver cancer, said: “Considering that patients with advanced HCC and severe liver dysfunction do not have any accepted standard of care, the current data from this Phase II trial suggest a signal of efficacy that supports continuing the development of Namodenoson with a Phase III study in this population.” Dr. Salomon Stemmer, the Israeli principal investigator, added: “Given the evidence of clinical benefit of Namodenoson, I plan on offering it t
Show less
Read more
Impact Snapshot
Event Time:
CANF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CANF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CANF alerts
High impacting Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares news events
Weekly update
A roundup of the hottest topics
CANF
News
- Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross ProceedsGlobeNewswire
- Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study [Yahoo! Finance]Yahoo! Finance
- Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer StudyGlobeNewswire
- Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of NamodenosonGlobeNewswire
- Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity TherapyGlobeNewswire
CANF
Sec Filings
- 3/5/26 - Form 424B3
- 3/5/26 - Form 6-K
- 3/4/26 - Form 6-K
- CANF's page on the SEC website